Myasthenia gravis (MG) is a rare autoimmune disorder caused by antibodies that act against the myoneural junction, resulting in weakness of the skeletal muscles. Prof. James Howard (The University of North Carolina at Chapel Hill, CA, USA) discusses the unmet needs in the treatment of this rare disease, including, quality of life of patients, response to treatment regimens, approved paediatric treatments, and treatments in pregnant women and family planning.
View more content from Prof. James Howard: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis – Results from the phase 3 CHAMPION-MG OLE trial
Questions:
- What are the unmet needs in the treatment of myasthenia gravis (MG)? (0:19)
Disclosures: James Howard receives grant/research Support from Alexion Pharmaceuticals, argenx BVBA, Cartesian Therapeutics, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI, Ra Pharmaceuticals (now UCB Biosciences), and Takeda Pharmaceuticals; he is on the advisory Board for Alexion Pharmaceuticals, argenx BVBA, and Ra Pharmaceuticals (now UCB Biosciences); and is a major stock shareholder in GlaxoSmithkline, JNJ, and Pfizer.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
